| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -447,530 | -273,088 |
| Depreciation | 2,655 | 1,599 |
| Stock-based compensation expense | 54,419 | 35,395 |
| Amortization of premiums and discounts on marketable securities, net | 11,037 | 8,632 |
| Gain on disposal of property and equipment | -83 | - |
| Non-cash operating lease costs | 2,672 | 1,645 |
| Prepaid and other assets | 140,283 | 116,078 |
| Accounts payable | 1,112 | -4,670 |
| Operating lease liabilities | - | -1,919 |
| Accrued expenses and other liabilities | 67,031 | 31,891 |
| Accrued compensation | - | 14,782 |
| Operating right-of-use assets and lease liabilities, net | -2,031 | - |
| Deferred revenue | -7,759 | -5,420 |
| Net cash used in operating activities | -480,668 | -324,495 |
| Proceeds from maturities of marketable securities | 862,604 | 593,040 |
| Purchases of marketable securities | 1,096,874 | 243,271 |
| Purchases of property and equipment | 7,808 | 7,096 |
| Tenant improvements capitalized to right-of-use assets | 3,175 | - |
| Net cash used in investing activities | -245,253 | 342,673 |
| Proceeds from issuance of common stock in public offerings, net of issuance costs | 837,420 | 0 |
| Proceeds from issuance of common stock under employee incentive equity plans | 18,656 | 5,710 |
| Proceeds from the issuance of common stock in a private placement, net of issuance costs | 0 | 0 |
| Proceeds from issuance of pre-funded warrants in a private placement, net of issuance costs | 0 | 0 |
| Net cash provided by financing activities | 856,076 | 5,710 |
| Effect of exchange rate on cash, cash equivalents and restricted cash | 138 | 154 |
| Net increase in cash, cash equivalents and restricted cash | 130,293 | 24,042 |
| Cash and cash equivalents at beginning of period | 222,663 | - |
| Cash and cash equivalents at end of period | 352,956 | - |
Avidity Biosciences, Inc. (RNA)
Avidity Biosciences, Inc. (RNA)